Related stories
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
BioMarin entered an exclusive license for a Fabry disease therapy from GC Biopharma and Hanmi Pharm.
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
National Medical Care Reports Q3 Net Profit of SAR 87.024 Million
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
Silicom Reports Q3 Revenue of $26.7 Million, Adjusted EPS of $0.04
M impact | EQUITY | Oct 29, 2026, 12:50 PM UTC
Al Baha reports Q3 net profit of SAR 2.66855 million
M impact | EQUITY | Oct 29, 2026, 12:49 PM UTC
Harley-Davidson Q3 EPS Falls 87% to $0.40; Revenue Drops 19%
Harley-Davidson reported Q3 2026 diluted EPS of $0.40, down 87% year over year, and revenue of $1.08 billion, down 19%.
M impact | EQUITY | Oct 29, 2026, 12:49 PM UTC
Mastercard Q3 Cross-Border Volume Growth Reaches 11%
Mastercard reported Q3 cross-border volume growth of 11% on a local currency basis.
L impact | EQUITY | Oct 29, 2026, 12:49 PM UTC